Alliances
Moderna and CytomX ink a cancer partnership.
In another early high-value deal, Amgen inked a licensing agreement with Synaffix for the development of next-generation antibody-drug conjugates.
Backed by Versant and Genentech, Belharra Therapeutics launched Wednesday with $130 million in total financing to advance its novel chemoproteomics platform.
Gilead and EVOQ Therapeutics announced a partnership to develop immunotherapies for rheumatoid arthritis and lupus.
Eli Lilly and ProQR Therapeutics expand their RNA-editing collaboration.
Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.
Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.
Jazz Pharmaceuticals exercised its option on Zymeworks’ promising anti-cancer agent.
Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.
Lilly digs deeper into metabolic diseases via GPCR partnership with Sosei.
PRESS RELEASES